搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
11 小时
天风证券:信达生物(01801)2024年中报符合预期 维持“买入”评级
智通财经APP获悉,天风证券发布研究报告称,维持信达生物(01801)“买入”评级,考虑到公司已上市产品持续放量,多条研发管线即将进入产品收获期,将2024和2025年的收入预期分别从72.25、91.93亿元上调至79.70、102.35亿元,预计2026年收入将达到131.43亿元。同时,将公司2024、2025年的净利润从-7.66、-1.70亿元调整至-7.56、0.89亿元,预计2026 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Inflation likely cooled again
Announces retirement
How to help Milton victims
Files suit against accuser
Increases heart attack risk?
Walz on Electoral College
Meat, poultry items recalled
Top colleges hit with lawsuit
Judge tosses New York law
273 'noncitizens' removed
Rare comet in October
US warns of solar storm
Ex-AR deputy sentenced
Ukraine meeting postponed
Russian arms depot struck
Mets advance to NLCS
Campaign, groups raise $1B
Idaho murder trial delayed
Faces $3B in penalties
Approves elimination of NLI
$273M Helene relief bill
GSK to settle 80K lawsuits
Georgia election board sued
Fat Bear Week winner
Monet painting returned
To settle FTC charges
SCOTUS hears appeal
反馈